Adenovir Pharma´s patent application relating to its invention entitled “Antiviral compounds, an aggregate comprising plurality of the compound and pharmaceutical composition comprising the same”, patent number 300794, has been granted by the Patent Office in India. Adenovir Pharma has an active patent strategy covering the major drugs markets.
Adenovir Pharma is developing a topical anti-viral pharmaceutical product for treatment of epidemic keratoconjunctivitis (EKC), by preventing adenoviruses from binding to the receptors in the human eye or infecting the corneal cells.
EKC is an eye infection caused by adenovirus – a worldwide health problem which today lacks efficient treatment. Typical symptoms are acute onset of severe pain, feeling or sensation that a foreign body is present in the eye, watering redness in the conjunctiva, edema and diminishing eyesight. Symptoms include inflammation in the conjunctiva (conjunctivitis) and in the cornea (keratitis).
For more information, please contact:
Björn Dellgren, CEO/project leader, Adenovir Pharma AB, email@example.com,
+46 (0)707 455 005